Status:

COMPLETED

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Lead Sponsor:

AbbVie

Collaborating Sponsors:

Roche-Genentech

Conditions:

Renal Impairment

Renal Disease

Eligibility:

FEMALE

18-75 years

Phase:

PHASE1

Brief Summary

Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female part...

Eligibility Criteria

Inclusion

  • Body mass index (BMI) between 18.0 and 42.0 kg/m2.
  • Postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
  • Women of childbearing potential, practicing at least 2 protocol specified methods of birth control that are effective from at least 30 days before starting study drug through at least 30 days after the last dose of any study drug.
  • Group 1 only: Must be in general good health based upon the results of a medical history, physical examination, and 12-lead electrocardiogram (ECG) with normal Glomerular Filtration Rate (GFR) at Screening.
  • Group 2 only: Stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile, and ECG. Participant with end stage renal disease (ESRD) requiring dialysis on hemodialysis must have been receiving hemodialysis for at least 1 month.

Exclusion

  • \- Participants on a strict vegetarian or vegan diet.

Key Trial Info

Start Date :

July 8 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 16 2022

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT04810598

Start Date

July 8 2021

End Date

August 16 2022

Last Update

September 16 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Orlando Clinical Research Ctr /ID# 224922

Orlando, Florida, United States, 32809

2

Acpru /Id# 243398

Grayslake, Illinois, United States, 60030